Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
Public ClinicalTrials.gov record NCT02006732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study identification
- NCT ID
- NCT02006732
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 809 participants
Conditions and interventions
Conditions
Interventions
- olodaterol Drug
- tiotropium Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2013
- Primary completion
- Sep 30, 2014
- Completion
- Oct 31, 2014
- Last update posted
- Jan 19, 2016
2013 – 2014
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1237.26.10620 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 1237.26.10618 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1237.26.10619 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1237.26.10614 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1237.26.10616 Boehringer Ingelheim Investigational Site | Duluth | Georgia | — | — |
| 1237.26.10613 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1237.26.10615 Boehringer Ingelheim Investigational Site | Greensboro | North Carolina | — | — |
| 1237.26.10603 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1237.26.10621 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 1237.26.10612 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1237.26.10605 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1237.26.10606 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1237.26.10610 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 1237.26.10607 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 1237.26.10617 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1237.26.10608 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1237.26.10604 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 1237.26.10609 Boehringer Ingelheim Investigational Site | Boerne | Texas | — | — |
| 1237.26.10602 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1237.26.10601 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02006732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2016 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02006732 live on ClinicalTrials.gov.